Costs related to the launch of its new Internet-related business led to lower 1999 revenues for film digitizer and computed radiography vendor Lumisys. The Sunnyvale, CA-based company saw its revenues decline approximately 17% to $4.3 million in the
Costs related to the launch of its new Internet-related business led to lower 1999 revenues for film digitizer and computed radiography vendor Lumisys. The Sunnyvale, CA-based company saw its revenues decline approximately 17% to $4.3 million in the fourth quarter (end-December), compared to revenues of $5.2 million for the same quarter of 1998. Net loss for the quarter was $460,000, compared to net income of $151,000 for the fourth quarter a year ago; losses were related primarily to the development to the companys new Internet portal business, AuntMinnie.com. Lumisys anticipates recording its first revenues from AuntMinnie.com in the first quarter of this year but also expects to record $970,000 in expenses during the quarter, which will affect overall operational results.
Revenues for 1999 were on a par with 1998: $19 million for 1999 and $19 million for 1998, while net loss for the year was $131,000, compared to net income of $894,000 for 1998. Including discontinued operations, Lumisys 1999 net loss was $4.3 million, stemming from charges related to the sale of the companys Imagraph subsidiary.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.